INdividualized Therapy FOr Relapsed Malignancies in Childhood (INFORM)
Although malignant diseases in childhood and adolescence can now be cured by about 80% with modern treatment protocols, relapses and the progression of high-risk diseases remain a major clinical challenge. There are no established treatment options for these cases. The INFORM registry study will help develop new treatment options for children and adolescents who have relapsed after initial therapy. For this purpose, the tumors of patients who have relapsed, and for whom there are no longer established treatment concepts available, are molecularly characterized as accurately as possible.
If you have further questions concerning the INFORM registry study, please contact: INFORM_info(at)dkfz.de
The concept of the INFORM program is to biologically characterize tumor specimens from routine biopsies of pediatric patients with relapsed or refractory high-risk disease for which no other standard therapy exists, regardless of histological diagnosis. State-of-the-art sequencing technologies are used to gain a "fingerprint" of each individual tumor. An expert panel - consisting of experienced pediatric oncologists, bioinformaticians, biologists and pharmacologists - classifies and assesses the changes and targets that could be found in each patient in terms of their clinical relevance. These molecular targets should be available in less than 4 weeks and entered into a centralized database. This study registry does not provide a therapy recommendation. The attending physician has access to his patient's molecular information / targets and is fully responsible for whether and how the data is used for a therapy decision. The goal is to include 260 patients from Germany and other international patients over a period of 2 years.
The purpose of the INFORM registry is to establish a technical, structural and genetic information base for future clinical trials (AMG) in the field of personalized pediatric oncology. More information can be found here. If you have any questions, please contact: INFORM_info(at)DKFZ.de
The INFORM consortium consists of leading physicians and scientists from the field of genomics, as well as pediatric oncology study groups of the pediatric oncology and hematology society (GPOH).
- Prof. Dr. med. Olaf Witt, KiTZ Director translational Program
Coordinator of the INFORM Registry Study and INFORM2
Head of the division Clinical Cooperation Unit Pediatric Oncology, DKFZ
Head of KiTZ Clinical Trial Unit (ZIPO) and Brain Tumors
Deputy Chief of the Department of Pediatric Oncology, Hematology Immunology and Pulmonology, (Pediatrics III), Heidelberg University Hospital
- Prof. Dr. med. Stefan Pfister, KiTZ Director Preclinical Program
Coordinator INFORM program
Head of the division Pediatric Neurooncology, DKFZ
Senior Physician for Pediatric Oncology, Hematology, Immunology and Pulmonology, (Pediatrics III), Heidelberg University Hospital
David T. W. Jones, PhD
Coordinator molecular diagnostics
Group Leader of Pediatric Glioma Research Group, DKFZ
Prof. Dr. Peter Lichter
Coordinator OMICs workflows
Head of the division Molecular Diagnostics, DKFZ
- Prof. Dr. med. Uta Dirksen
Coordinator participating GPOH groups
Vice Director Pediatrics III, Oncology, Hematology, Immunology, Cardiology, Pulmonology, West German Cancer Centre, Essen
Anyone who is eligible to participate in the INFORM register will be identified by the attending children's oncologist. Inclusion criteria include tumor progression or progressive diseasse with the diagnosis of ALL-HR, ALL post-SCT, AML, rhabdoid tumors, ependymoma, medulloblastoma, Ewing's sarcoma, high-grade glioma (including diffuse intrinsic ponsglioma), high-risk neuroblastoma, non-Hodgkin's lymphoma, osteosarcoma, soft tissue sarcoma and, in isolated cases, other rare tumors for which there are no established curative treatments. Patients are between 1 and 40 years of age and were treated as part of their primary diagnosis in a treatment protocol from the Society for Pediatric Oncology and Hematology (GPOH) or an equivalent treatment protocol. Exceptions are specific soft tissue sarcomas for which there are no curative treatment options in the primary situation, as well as the diffuse intrinsic pons glioma. Patients may be admitted until the age of 40, but the primary diagnosis must be made before the age of 21. In addition, given the duration of the analysis, only patients who have a life expectancy of at least 3 months and are in good general condition can participate. The tumor material is obtained as part of the routine care of patients.
Patients (and / or parents) are informed by their attending child oncologist via the INFORM registry and sign the consent form. After reviewing the inclusion and exclusion criteria, the treating oncologist can electronically register the patient with the INFORM register. Without this electronic application, no examinations can be performed. Only a pediatric oncologist can register a patient with the INFORM register.
A panel of experts (experienced children's oncologists, bioinformaticians, biologists, pharmacologists) classify the changes found according to clinical relevance for each individual patient. The register does not provide any therapy recommendations, only the molecular information. The pediatric oncologist has access to the acquired biological information of the patient and can decide independently whether and how it is used for the therapeutic decision.
Please direct your inquiries to the following contact: INFORM_info(at)dkfz.de